The FDA has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines Canagliflozin (Invokana, Invokamet) and Dapagliflozin (Farxiga, Xigduo XR). The labels now include information about acute kidney injury and recommendations to minimize this risk. For full details see http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm506554.htm .
